Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321127 | 0.84 | KDM4E (0.59) | GRM5ALDH1A1KDM4ETDP1ALOX15 | |
| SCHEMBL960010 | 0.82 | ALDH1A1 (0.51) | GRM5ALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL4989 | 0.80 | KDM4E (0.70) | GRM5ALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL29940784 | 0.80 | KDM4E (0.70) | GRM5ALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL13932169 | 0.80 | KDM4E (0.50) | GRM5ALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL25307554 | 0.78 | ALDH1A1 (0.49) | GRM5ALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL6744 | 0.78 | GRM5 (0.51) | GRM5ALDH1A1HPGDKDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL4538345 | 0.78 | KDM4E (0.67) | GRM5ALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL2825924 | 0.78 | ALDH1A1 (0.49) | GRM5ALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL30041316 | 0.78 | GRM5 (0.51) | GRM5ALDH1A1HPGDKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109593085-B | Pyridine-amide-oxazoline ligand, synthetic method thereof, metal complex thereof and application thereof | 温州大学 | 2021-01-15 | — | — | CN | claimed |
| CN-109593085-A | Pyridine-amide-oxazoline ligand, its synthetic method and its metal complex and purposes | 温州大学 | 2019-04-09 | — | — | CN | claimed |
| CN-105801592-A | Preparation method of podophyllotoxin picolinic formic ether derivative and application of derivative to anti-leukemia drug | 遵义医学院 | 2016-07-27 | — | — | CN | claimed |
| EP-4551218-A2 | POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 | Dana-Farber Cancer Institute, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240410831-A1 | Multi-Mode Zinc-Selective Emission-Ratiometric Fluorescent Probes for Biological Application | GEORGIA TECH RESEARCH CORPORATION | 2024-12-12 | — | — | US | disclosed |
| EP-4370512-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | Cytokinetics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024011116-A2 | POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC (US) | 2023-04-06 | — | — | US | disclosed |
| WO-2023288195-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-101023063-A | Azine-carboxamides as anti-cancer agents | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | CN | disclosed |
| EP-1765790-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006114400-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-11-02 | — | — | WO | disclosed |
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-20060147747-A1 | 2-[4-(10-naphthalene-2-yl-anthracene-9-yl)-phenyl]-1-phenyl-1H-benzimidazole; elevation of luminance and of efficiency in light emission even under low driving voltage | IDEMITSU KOSAN CO., LTD. (JP) | 2006-07-06 | — | — | US | disclosed |
| WO-2006003378-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1602648-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-5614634-A | Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5440044-A | Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | GRM5 4272/4885ALDH1A1 2869/4885HPGD 286/4885 |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | GRM5 2518/4885ALDH1A1 358/4885HPGD 754/4885 |
| US-11787783-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | GRM5 1116/4885ALDH1A1 1394/4885HPGD 246/4885 |
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | SYK, BTK, ZAP70 | GRM5 1267/4885ALDH1A1 3188/4885HPGD 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.